Increased Cytoplasmic CD138 Expression Is Associated with Aggressive Characteristics in Prostate Cancer and Is an Independent Predictor for Biochemical Recurrence
Table 1
Study cohort.
No. of patients (%)
Study cohort on TMA ()
Biochemical relapse among categories
Follow-up (mo)
14464 (81.5%)
3612 (25%)
Mean
56.3
—
Median
48
—
Age (y)
≤50
433 (2.4%)
66 (15.2%)
51-59
4341 (24.5%)
839 (19.3%)
60-69
9977 (56.4%)
2073 (20.8%)
≥70
2936 (16.6%)
634 (21.6%)
Pretreatment PSA (ng/ml)
<4
2225 (12.6%)
313 (14.1%)
4-10
10520 (59.6%)
1696 (16.1%)
10-20
3662 (20.8%)
1043 (28.5%)
>20
1231 (7%)
545 (44.3%)
pT stage (AJCC 2002)
pT2
11518 (65.2%)
1212 (10.5%)
pT3a
3842 (21.7%)
1121 (29.2%)
pT3b
2233 (12.6%)
1213 (54.3%)
pT4
85 (0.5%)
63 (74.1%)
Gleason grade
≤3+3
3570 (20.3%)
264 (7.4%)
3+4
9336 (53%)
1436 (15.4%)
3+4 Tert.5
798 (4.5%)
165 (20.7%)
4+3
1733 (9.8%)
683 (39.4%)
4+3 Tert.5
1187 (6.7%)
487 (41%)
≥4+4
999 (5.7%)
531 (53.2%)
pN stage
pN0
10636 (89.4%)
2243 (21.1%)
pN+
1255 (10.6%)
700 (55.8%)
Surgical margin
Negative
14297 (80.8%)
2307 (16.1%)
Positive
3388 (19.2%)
1304 (38.5%)
Percent in the column “Study cohort on TMA” refers to the fraction of samples across each category. Percent in column “Biochemical relapse among categories” refers to the fraction of samples with biochemical relapse within each parameter in the different categories. Numbers do not always add up to 17,747 in the different categories because of cases with missing data. AJCC: American Joint Committee on Cancer.
